Top

Published in:

01-09-2009

Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience

Authors: Giselle Fernandes Taboada, Ana Lúcia Osório Tabet, Luciana A. Naves, Denise Pires de Carvalho, Mônica Roberto Gadelha

Published in: Pituitary | Issue 3/2009

Abstract

The purpose of the present study is to evaluate the prevalence of the gsp oncogene in Brazilian patients harboring somatotropinomas and non-functioning pituitary adenomas (NFPA). Patients and methods Deoxyribonucleic acid was extracted from 54 somatotropinomas and 14 NFPA. Exons 8 and 9 (including codons 201 and 227, respectively) of the GNAS gene were amplified by polymerase chain reaction (PCR). The PCR products were then purified and sequenced using the same primers. Results The gsp oncogene was found in nine tumors (eight somatotropinomas). The prevalence among somatotropinomas was 15% and among NFPA was 7%. The mutation was found in codon 201 in eight tumors and in codon 227 in one tumor (a somatotropinoma). No differences were found in age, sex, GH, and IGF-I levels or tumor volume at diagnosis between gsp+ and gsp− patients. Conclusion We found a lower than expected prevalence of gsp mutations in somatotropinomas and a similar prevalence in NFPA compared to previous studies from other countries.

Spiegel AM (1996) Mutations in G proteins and G protein-coupled receptors in endocrine disease. J Clin Endocrinol Metab 81:2434–2442. doi:10.1210/jc.81.7.2434 PubMedCrossRef

Landis CA, Masters SB, Spada A et al (1989) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumors. Nature 340:692–696. doi:10.1038/340692a0 PubMedCrossRef

Williamson EA, Ince PG, Harrison D et al (1995) G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas. Eur J Clin Invest 25:128–131. doi:10.1111/j.1365-2362.1995.tb01537.x PubMedCrossRef

Riminucci M, Collins MT, Lala R et al (2002) An R201H activating mutation of the GNAS1 (Gsalpha) gene in a corticotroph pituitary adenoma. Mol Pathol 55:58–60. doi:10.1136/mp. 55.1.58 PubMedCrossRef

Tordjman K, Stern N, Ouaknine G et al (1993) Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors. J Clin Endocrinol Metab 77:765–769. doi:10.1210/jc.77.3.765 PubMedCrossRef

Williamson EA, Daniels M, Foster S et al (1994) Gs alpha and Gi2 alpha mutations in clinically non-functioning pituitary tumors. Clin Endocrinol (Oxf) 41:815–820. doi:10.1111/j.1365-2265.1994.tb02798.x CrossRef

Landis CA, Harsh G, Lyons J et al (1990) Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J Clin Endocrinol Metab 71:1416–1420PubMed

Drews RT, Gravel RA, Collu R (1992) Identification of G protein alpha subunit mutations in human growth hormone (GH)- and GH/prolactin-secreting pituitary tumors by single-strand conformation polymorphism (SSCP) analysis. Mol Cell Endocrinol 87:125–129. doi:10.1016/0303-7207(92)90240-7 PubMedCrossRef

Yoshimoto K, Iwahana H, Fukuda A et al (1993) Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis. Cancer 72:1386–1393. doi :10.1002/1097-0142(19930815)72:4<1386::AID-CNCR2820720439>3.0.CO;2-JPubMedCrossRef

10.

Hosoi E, Yokogoshi Y, Hosoi E et al (1993) Analysis of the Gs alpha gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues. Acta Endocrinol (Copenh) 129:301–306

11.

Adams EF, Brockmeier S, Friedmann E et al (1993) Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery 33:198–203. doi:10.1097/00006123-199308000-00003 PubMedCrossRef

12.

Yang I, Park S, Ryu M et al (1996) Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol 134:720–726PubMedCrossRef

13.

Shi Y, Tang D, Deng J et al (1998) Detection of gsp oncogene in growth hormone-secreting pituitary adenomas and the study of clinical characteristics of acromegalic patients with gsp-positive pituitary tumors. Chin Med J 111:891–894PubMed

14.

Ballaré E, Mantovani S, Lania A et al (1998) Activating mutations of the Gs alpha gene are associated with low levels of Gs alpha protein in growth hormone-secreting tumors. J Clin Endocrinol Metab 83:4386–4390. doi:10.1210/jc.83.12.4386 PubMedCrossRef

15.

Barlier A, Gunz G, Zamora AJ et al (1998) Prognostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 83:1604–1610. doi:10.1210/jc.83.5.1604 PubMedCrossRef

16.

Buchfelder M, Fahlbusch R, Merz T et al (1999) Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes. Pituitary 1:181–185. doi:10.1023/A:1009905131334 PubMedCrossRef

17.

Johnson MC, Codner E, Eggers M et al (1999) Gps mutations in Chilean patients harboring growth hormone-secreting pituitary tumors. J Pediatr Endocrinol Metab 12:381–387PubMed

18.

Kim HJ, Kim MS, Park YJ et al (2001) Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas. J Endocrinol 168:221–226. doi:10.1677/joe.0.1680221 PubMedCrossRef

19.

Corbetta S, Ballaré E, Mantovani G et al (2001) Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 31:208–214. doi:10.1046/j.1365-2362.2001.00786.x PubMedCrossRef

20.

Kan B, Esapa C, Sipahi T et al (2003) G protein mutations in pituitary tumors: a study on Turkish patients. Pituitary 6:75–80. doi:10.1023/B:PITU.0000004797.89592.5e PubMedCrossRef

21.

Park C, Yang I, Woo J et al (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to octreotide. Endocr J 51:227–236. doi:10.1507/endocrj.51.227 PubMedCrossRef

22.

Mendoza V, Sosa E, Espinosa-de-Los-Monteros AL et al (2005) GSPalpha mutations in Mexican patients with acromegaly: potential impact on long term prognosis. Growth Horm IGF Res 15:28–32. doi:10.1016/j.ghir.2004.10.001 PubMedCrossRef

23.

Yasufuku-Takano J, Takano K, Morita K et al (2006) Does the prevalence of gsp mutations in GH-secreting pituitary adenomas differ geographically or racially? Prevalence of gsp mutations in Japanese patients revisited. Clin Endocrinol (Oxf) 64:91–96. doi:10.1111/j.1365-2265.2005.02423.x CrossRef

24.

Metzler M, Luedecke DK, Saeger W et al (2006) Low prevalence of Gs alpha mutations in śomatotroph adenomas of children and adolescents. Cancer Genet Cytogenet 166:146–151. doi:10.1016/j.cancergencyto.2005.11.001 PubMedCrossRef

25.

Freda PU, Chung WK, Matsuoka N et al (2007) Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary 10:275–282. doi:10.1007/s11102-007-0058-2 PubMedCrossRef

26.

Spada A, Arosio M, Bochicchio D et al (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71:1421–1426PubMed

27.

Jallad RS, Musolino NR, Salgado LR et al (2005) Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63:168–175. doi:10.1111/j.1365-2265.2005.02317.x CrossRef

28.

Freda PU, Katznelson L, van der Lely AJ et al (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465–4473. doi:10.1210/jc.2005-0260 PubMedCrossRef

29.

Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674. doi:10.1210/jc.2003-031199 PubMedCrossRef

30.

Ayuk J, Clayton RN, Holder G et al (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613–1617. doi:10.1210/jc.2003-031584 PubMedCrossRef

Title: Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience
Authors: Giselle Fernandes Taboada
Ana Lúcia Osório Tabet
Luciana A. Naves
Denise Pires de Carvalho
Mônica Roberto Gadelha
Publication date: 01-09-2009
Publisher: Springer US
Published in: Pituitary / Issue 3/2009
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-008-0136-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Adjuvant Gamma Knife radiosurgery in non-functioning pituitary adenomas; low risk of long-term complications in selected patients

Future treatment strategies of aggressive pituitary tumors

Pituitary-hormone secretion by thyrotropinomas

Transient asystole during endoscopic transsphenoidal surgery: an example of trigeminocardiac reflex

Simultaneous above and below approach to giant pituitary adenomas: surgical strategies and long-term follow-up

The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials